<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">9500169</journal-id>
<journal-id journal-id-type="pubmed-jr-id">20475</journal-id>
<journal-id journal-id-type="nlm-ta">Neurobiol Dis</journal-id>
<journal-id journal-id-type="iso-abbrev">Neurobiol. Dis.</journal-id>
<journal-title-group>
<journal-title>Neurobiology of disease</journal-title>
</journal-title-group>
<issn pub-type="ppub">0969-9961</issn>
<issn pub-type="epub">1095-953X</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28993242</article-id>
<article-id pub-id-type="pmc">6070303</article-id>
<article-id pub-id-type="doi">10.1016/j.nbd.2017.10.004</article-id>
<article-id pub-id-type="manuscript">NIHMS913147</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>A distinct microRNA expression profile is associated with α[<sup>11</sup>C]-methyl-L-tryptophan (AMT) PET uptake in epileptogenic cortical tubers resected from patients with tuberous sclerosis complex</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Bagla</surname>
<given-names>Shruti</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cukovic</surname>
<given-names>Daniela</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Asano</surname>
<given-names>Eishi</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sood</surname>
<given-names>Sandeep</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Luat</surname>
<given-names>Aimee</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chugani</surname>
<given-names>Harry T.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chugani</surname>
<given-names>Diane C.</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Dombkowski</surname>
<given-names>Alan A.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI, USA</aff>
<aff id="A2">
<label>2</label>Department of Neurology, Nemours/Alfred I. duPont Hospital for Children, Wilmington, DE, USA</aff>
<aff id="A3">
<label>3</label>Research Department, Nemours/Alfred I. duPont Hospital for Children, Wilmington, DE, USA</aff>
<aff id="A4">
<label>4</label>Communication Sciences and Disorders Department, College of Health Sciences, University of Delaware, Newark, DE, USA</aff>
<author-notes>
<corresp id="FN1">Address correspondence to: Dr. Alan Dombkowski, Division of Clinical Pharmacology and Toxicology, Department of Pediatrics, Room 3L22, Children's Hospital of Michigan, 3901 Beaubien Blvd, Detroit, MI 48201, USA. <email>domski@wayne.edu</email></corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>14</day>
<month>10</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>07</day>
<month>10</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<month>1</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>1</month>
<year>2019</year>
</pub-date>
<volume>109</volume>
<issue>Pt A</issue>
<fpage>76</fpage>
<lpage>87</lpage>
<!--elocation-id from pubmed: 10.1016/j.nbd.2017.10.004-->
<abstract id="Abs1">
<p id="P1">Tuberous sclerosis complex (TSC) is characterized by hamartomatous lesions in various organs and arises due to mutations in the <italic>TSC1</italic> or <italic>TSC2</italic> genes. TSC mutations lead to a range of neurological manifestations including epilepsy, cognitive impairment, autism spectrum disorders (ASD), and brain lesions that include cortical tubers. There is evidence that seizures arise at or near cortical tubers, but it is unknown why some tubers are epileptogenic while others are not. We have previously reported increased tryptophan metabolism measured with α[<sup>11</sup>C]-methyl-<sc>l</sc>-tryptophan (AMT) positron emission tomography (PET) in epileptogenic tubers in approximately two-thirds of patients with tuberous sclerosis and intractable epilepsy. However, the underlying mechanisms leading to seizure onset in TSC remain poorly characterized. MicroRNAs are enriched in the brain and play important roles in neurodevelopment and brain function. Recent reports have shown aberrant microRNA expression in epilepsy and TSC. In this study, we performed microRNA expression profiling in brain specimens obtained from TSC patients undergoing epilepsy surgery for intractable epilepsy. Typically, in these resections several non-seizure onset tubers are resected together with the seizure-onset tubers because of their proximity. We directly compared seizure onset tubers, with and without increased tryptophan metabolism measured with PET, and non-onset tubers to assess the role of microRNAs in epileptogenesis associated with these lesions. Whether a particular tuber was epileptogenic or non-epileptogenic was determined with intracranial electrocorticography, and tryptophan metabolism was measured with AMT PET. We identified a set of five microRNAs (miR-142-3p, 142-5p, 223-3p, 200b-3p and 32-5p) that collectively could distinguish among the three primary groups of tubers: non-onset/AMT-cold (NC), onset/AMT-cold (OC), and onset/AMT-hot (OH). These microRNAs were significantly upregulated in OH tubers compared to the other two groups, and microRNA expression was most significantly associated with AMT-PET uptake. The microRNAs target a group of genes enriched for synaptic signaling and epilepsy risk, including <italic>SLC12A5, SYT1, GRIN2A, GRIN2B, KCNB1, SCN2A, TSC1, and MEF2C</italic>. We confirmed the interaction between miR-32-5p and <italic>SLC12A5</italic> using a luciferase reporter assay. Our findings provide a new avenue for subsequent mechanistic studies of tuber epileptogenesis in TSC.</p>
</abstract>
<abstract abstract-type="graphical" id="Abs2">
<title>Graphical abstract</title>
<p id="P2">
<graphic orientation="portrait" position="anchor" xlink:href="nihms913147u1.jpg"></graphic></p>
</abstract>
<kwd-group>
<kwd>Tuberous sclerosis complex</kwd>
<kwd>epilepsy</kwd>
<kwd>seizure</kwd>
<kwd>microRNA</kwd>
<kwd>tryptophan</kwd>
<kwd>α[<sup>11</sup>C]-methyl-L-tryptophan</kwd>
<kwd>positron emission tomography</kwd>
<kwd>gene expression</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>